AKRO AKERO THERAPEUTICS INC

Ownership history in MORGAN STANLEY  ·  26 quarters on record

This page tracks every 13F SEC filing in which MORGAN STANLEY reported a position in AKERO THERAPEUTICS INC (AKRO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 339,922 -353,334 -51.0% 0.00% $16.1M
2025 Q2 REDUCED 693,256 -109,598 -13.7% 0.00% $37.0M
2025 Q1 ADDED 802,854 +331,319 +70.3% 0.00% $32.5M
2024 Q4 ADDED 471,535 +23,465 +5.2% 0.00% $13.1M
2024 Q3 REDUCED 448,070 -498,458 -52.7% 0.00% $12.9M
2024 Q2 ADDED 946,528 +542,665 +134.4% 0.00% $22.2M
2024 Q1 REDUCED 403,863 -653,464 -61.8% 0.00% $10.2M
2023 Q4 ADDED 1,057,327 +617,591 +140.4% 0.00% $24.7M
2023 Q3 ADDED 439,736 +54,078 +14.0% 0.00% $22.2M
2023 Q2 ADDED 385,658 +28,065 +7.8% 0.00% $18.0M
16 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)

Other funds also holding AKRO

As of 2025 Q4 — sorted by position size

Nebula Research & Development LLC 0.07% IFP Advisors, Inc 3Y 7Y 0.0%
← Back to MORGAN STANLEY Holdings